

Wybrane publikacje:

1. Neurokinin-1 receptor-based bivalent drugs in pain management: The journey to nowhere? Kleczkowska P, Nowicka K, Bujalska-Zadrozny M, Hermans E. *Pharmacol Ther.* 2018 Nov 20. pii: S0163-7258(18)30210-9. doi: 10.1016/j.pharmthera.2018.11.007. [Epub ahead of print] Review.
2. The problem of mephedrone in Europe: Causes and suggested solutions. Ordak M, Nasierowski T, Bujalska-Zadrozny M. *Eur Psychiatry.* 2018 Oct 29;55:43-44. doi: 10.1016/j.eurpsy.2018.09.001. [Epub ahead of print] No abstract available.
3. Bidirectional selection for high and low stress-induced analgesia affects G-protein activity. Poznański P, Lesniak A, Bujalska-Zadrozny M, Strzemecka J, Sacharczuk M. *Neuropharmacology.* 2019 Jan;144:37-42. doi: 10.1016/j.neuropharm.2018.10.014. Epub 2018 Oct 13.
4. Inhibitory effect of *Ligustrum vulgare* leaf extract on the development of neuropathic pain in a treptozotocin-induced rat model of diabetes. Czerwińska ME, Gąsińska E, Leśniak A, Krawczyk P, Kiss AK, Naruszewicz M, Bujalska-Zadrozny M. *Phytomedicine.* 2018 Oct 1;49:75-82. doi: 10.1016/j.phymed.2018.06.006. Epub 2018 Jun 11.
5. Awareness and attitudes towards clinical trials among Polish oncological patients who had never participated in a clinical trial. Staniszevska A, Lubiejewska A, Czerw A, Dąbrowska-Bender M, Duda-Zalewska A, Olejniczak D, Juszczyk G, Bujalska-Zadrozny M. *Adv Clin Exp Med.* 2018 Apr;27(4):525-529. doi: 10.17219/acem/68762.
6. 6. ADVANCES IN PHARMACOTHERAPY OF TUBERCULOSIS. Pstragowski M, Zbrzezna M, Bujalska-Zadrozny M. *Acta Pol Pharm.* 2017 Jan;74(1):3-11. Review.
7. 7. Disulfiram attenuates morphine or methadone withdrawal syndrome in mice. de Cordé A, Krząścik P, Wolińska R, Kleczkowska P, Filip M, Bujalska-Zadrozny M. *Behav Pharmacol.* 2018 Aug;29(5):393-399. doi: 10.1097/FBP.0000000000000376.
8. Level of magnesium in psychiatry - What is the cause of ambiguous results? Ordak M, Muszynska E, Nasierowski T, Maj-Zurawska M, Bujalska-Zadrozny M. *Gen Hosp Psychiatry.* 2018 Mar - Apr;51:136. doi: 10.1016/j.genhosppsy.2017.11.002. Epub 2017 Nov 10. No abstract available.
9. Effect of Disturbances of Zinc and Copper on the Physical and Mental Health Status of Patients with Alcohol Dependence. Ordak M, Bulska E, Jablonka-Salach K, Luciuk A, Maj-Zurawska M, Matsumoto H, Nasierowski T, Wojnar M, Matras J, Muszynska E, Bujalska-Zadrozny M. *Biol Trace Elem Res.* 2018 May;183(1):9-15. doi: 10.1007/s12011-017-1113-0. Epub 2017 Aug 12.
10. Ionized magnesium in plasma and erythrocytes for the assessment of low magnesium status in alcohol dependent patients. Ordak M, Maj-Zurawska M, Matsumoto H, Bujalska-Zadrozny M, Kieres-Salomonski I, Nasierowski T, Muszynska E, Wojnar M. *Drug Alcohol Depend.* 2017 Sep 1;178:271-276. doi: 10.1016/j.drugalcdep.2017.04.035. Epub 2017 Jun 24.
11. Magnesium in schizophrenia. Ordak M, Matras J, Muszynska E, Nasierowski T, Bujalska-Zadrozny M. *Pharmacol Rep.* 2017 Oct;69(5):929-934. doi: 10.1016/j.pharep.2017.03.022. Epub 2017 Apr 12. Review.

12. Delta-opioid receptor antagonism leads to excessive ethanol consumption in mice with enhanced activity of the endogenous opioid system. Poznanski P, Lesniak A, Korostynski M, Szklarczyk K, Lazarczyk M, Religa P, Bujalska-Zadrozny M, Sadowski B, Sacharczuk M. *Neuropharmacology*. 2017 May 15;118:90-101. doi: 10.1016/j.neuropharm.2017.03.016. Epub 2017 Mar 18.
13. Naloxone exacerbates memory impairments and depressive-like behavior after mild traumatic brain injury (mTBI) in mice with upregulated opioid system activity. Lesniak A, Leszczynski P, Bujalska-Zadrozny M, Pick CG, Sacharczuk M. *Behav Brain Res*. 2017 May 30;326:209-216. doi: 10.1016/j.bbr.2017.03.015. Epub 2017 Mar 8.
14. Antinociceptive effect of co-administered NMDA and histamine H4 receptor antagonists in a rat model of acute pain. Wolińska R, Leśniak A, Żochowska M, Sacharczuk M, Kieć-Kononowicz K, Bujalska-Zadrozny M. *Pharmacol Rep*. 2017 Apr;69(2):222-228. doi: 10.1016/j.pharep.2016.10.018. Epub 2016 Oct 29.
15. New agents approved for treatment of acute staphylococcal skin infections. Tatariewicz J, Staniszewska A, Bujalska-Zadrozny M. *Arch Med Sci*. 2016 Dec 1;12(6):1327-1336. Epub 2016 May 11.
16. Magnesium enhances opioid-induced analgesia - What we have learnt in the past decades? Bujalska-Zadrozny M, Tatariewicz J, Kulik K, Filip M, Naruszewicz M. *Eur J Pharm Sci*. 2017 Mar 1;99:113-127. doi: 10.1016/j.ejps.2016.11.020. Epub 2016 Nov 21. Review.
17. Esculetin reduces leukotriene B4 level in plasma of rats with adjuvant-induced arthritis. Rzedkiewicz P, Gąsińska E, Gajewski M, Bujalska-Zadrozny M, Szukiewicz D, Maśliński S. *Reumatologia*. 2016;54(4):161-164. Epub 2016 Oct 5.
18. Micronized Organic Magnesium Salts Enhance Opioid Analgesia in Rats. Bujalska-Zadrozny M, Kulik K, Ordak M, Sasinowska-Motyl M, Gąsińska E, de Corde A, Kowalczyk A, Sacharczuk M, Naruszewicz M. *PLoS One*. 2016 Oct 28;11(10):e0161776. doi: 10.1371/journal.pone.0161776. eCollection 2016.
19. The Discovery and Development of Drug Combinations for the Treatment of Various Diseases from Patent Literature (1980-Present). Kleczkowska P, Kowalczyk A, Lesniak A, Bujalska-Zadrozny M. *Curr Top Med Chem*. 2017;17(8):875-894. doi: 10.2174/1568026616666160818152257. Review.
20. Central antinociceptive effect of tapentadol is increased by nitric oxide synthase inhibitors. Bujalska-Zadrozny M, Wolińska R, Leśniak A, Sacharczuk M. *Behav Pharmacol*. 2016 Oct;27(7):606-14. doi: 10.1097/FBP.0000000000000255.
21. Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users? Kleczkowska P, Smaga I, Filip M, Bujalska-Zadrozny M. *Neurotox Res*. 2016 Nov;30(4):698-714. Epub 2016 Aug 2. Review.
22. Antinociceptive effect induced by a combination of opioid and neurotensin moieties vs. their hybrid peptide [Ile(9)]PK20 in an acute pain treatment in rodents. Kleczkowska P, Hermans E, Kosson P, Kowalczyk A, Lesniak A, Pawlik K, Bojnik E, Benyhe S, Nowicka B, Bujalska-Zadrozny M, Misicka A, Lipkowski AW. *Brain Res*. 2016 Oct 1;1648(Pt A):172-180. doi: 10.1016/j.brainres.2016.07.039. Epub 2016 Jul 26.

23. Biological evaluation and molecular docking studies of AA3052, a compound containing a μ -selective opioid peptide agonist DALDA and d-Phe-Phe-d-Phe-Leu-Leu-NH₂, a substance P analogue. Kowalczyk A, Kleczkowska P, Rękawek M, Kulik K, Lesniak A, Erdei A, Borics A, Martin C, Pawlik K, Lipkowski AW, Benyhe S, Makulska-Nowak H, Ballet S, Bujalska-Zadrozny M. *Eur J Pharm Sci.* 2016 Oct 10;93:11-20. doi: 10.1016/j.ejps.2016.07.009. Epub 2016 Jul 14.
24. INHIBITORS OF LEUKOTRIENES SYNTHESIS: NOVEL AGENTS AND THEIR IMPLEMENTATION. Cegielska-Perun K, Marczuk E, Bujalska-Zadrozny M. *Acta Pol Pharm.* 2016 Jul;73(4):843-849. Review.
25. Biphalin preferentially recruits peripheral opioid receptors to facilitate analgesia in a mouse model of cancer pain - A comparison with morphine. Lesniak A, Bochynska-Czyz M, Sacharczuk M, Benhye S, Misicka A, Bujalska-Zadrozny M, Lipkowski AW. *Eur J Pharm Sci.* 2016 Jun 30;89:39-49. doi: 10.1016/j.ejps.2016.04.014. Epub 2016 Apr 14.
26. Antinociceptive activity of intraperitoneally administered novel and potent anticonvulsive compound, CY-PROLL-SS, in animal neuropathic pain models. Bujalska-Zadrozny M, Kogut E, de Cordé A, Dawidowski M, Kleczkowska P. *Pharmacol Rep.* 2016 Jun;68(3):601-7. doi: 10.1016/j.pharep.2016.01.001. Epub 2016 Jan 21.
27. Synthesis and binding characteristics of [(3)H]neuromedin N, a NTS2 receptor ligand. Tóth F, Mallareddy JR, Tourwé D, Lipkowski AW, Bujalska-Zadrozny M, Benyhe S, Ballet S, Tóth G, Kleczkowska P. *Neuropeptides.* 2016 Jun;57:15-20. doi: 10.1016/j.npep.2015.12.004. Epub 2015 Dec 8.
28. Genetic and environmental predictors of chronic kidney disease in patients with type 2 diabetes and diabetic foot ulcer: a pilot study. Mrozikiewicz-Rakowska B, Maroszek P, Nehring P, Sobczyk-Kopciol A, Krzyzewska M, Kaszuba AM, Lukawska M, Chojnowska N, Kozka M, Bujalska-Zadrozny M, Ploski R, Krzymien J, Czupryniak L. *J Physiol Pharmacol.* 2015 Oct;66(5):751-61.
29. The effect of opioid agonists and antagonists on gastrointestinal motility in mice selected for high and low swim stress-induced analgesia. Wasilewski A, Lesniak A, Bujalska-Zadrozny M, Sadowski B, Fichna J, Sacharczuk M. *Neurogastroenterol Motil.* 2016 Feb;28(2):175-85. doi: 10.1111/nmo.12704. Epub 2015 Oct 28.
30. Acyldepsipeptide antibiotics--current state of knowledge. Pstrągowski MT, Bujalska-Zadrozny M. *Pol J Microbiol.* 2015;64(2):85-92. Review.
31. Cannabinoid Ligands and Alcohol Addiction: A Promising Therapeutic Tool or a Humbug? Kleczkowska P, Smaga I, Filip M, Bujalska-Zadrozny M. *Neurotox Res.* 2016 Jan;29(1):173-96. doi: 10.1007/s12640-015-9555-7. Epub 2015 Sep 9. Review.
32. Effects of the Hybridization of Opioid and Neurotensin Pharmacophores on Cell Survival in Rat Organotypic Hippocampal Slice Cultures. Kleczkowska P, Kawalec M, Bujalska-Zadrozny M, Filip M, Zablocka B, Lipkowski AW. *Neurotox Res.* 2015 Nov;28(4):352-60. doi: 10.1007/s12640-015-9553-9. Epub 2015 Aug 19.
33. Influence of nitric oxide synthase or cyclooxygenase inhibitors on cannabinoids activity in streptozotocin-induced neuropathy. Bujalska-Zadrozny M, de Cordé A, Pawlik K. *Pharmacol Rep.* 2015 Apr;67(2):209-16. doi: 10.1016/j.pharep.2014.08.023. Epub 2014 Sep 16.

34. Mechanisms of morphine-venlafaxine interactions in diabetic neuropathic pain model. Cegielska-Perun K, Tatarkiewicz J, Siwek A, Dybała M, Bujalska-Zadrożny M. *Pharmacol Rep.* 2015 Feb;67(1):90-6. doi: 10.1016/j.pharep.2014.08.008. Epub 2014 Aug 21.
35. Tapentadol and nitric oxide synthase systems. Bujalska-Zadrożny M, Wolińska R, Gąsińska E, Nagraba Ł. *Behav Pharmacol.* 2015 Apr;26(3):282-8. doi: 10.1097/FBP.000000000000117.
36. Antinociceptive properties of esculetin in non-inflammatory and inflammatory models of pain in rats. Rzdokiewicz P, Gasinska E, Maslinski S, Bujalska-Zadrożny M. *Clin Exp Pharmacol Physiol.* 2015 Feb;42(2):213-9. doi: 10.1111/1440-1681.12346.
37. Enhancement of antinociceptive effect of morphine by antidepressants in diabetic neuropathic pain model. Cegielska-Perun K, Bujalska-Zadrożny M, Gąsińska E, Makulska-Nowak HE. *Pharmacol Rep.* 2014 Apr;66(2):228-34. doi: 10.1016/j.pharep.2013.09.003. Epub 2014 Mar 4.
38. Additive effect of combined application of magnesium and MK-801 on analgesic action of morphine. Bujalska-Zadrożny M, Duda K. *Pharmacology.* 2014;93(3-4):113-9. doi: 10.1159/000358255. Epub 2014 Feb 26.
39. Sampling intervals verification in pharmacokinetics studies. Grabowski T, Jaroszewski JJ, Sasinowska-Motyl M, Bujalska-Zadrożny M. *Drug Res (Stuttg).* 2014 Aug;64(8):442-7. doi: 10.1055/s-0033-1361143. Epub 2013 Dec 10. Ethanol consumption following mild traumatic brain injury is related to blood-brain barrier permeability. Poznanski P, Lesniak A, Korostynski M, Sacharczuk M. *Addict Biol.* 2018 Oct 18. doi: 10.1111/adb.12683. [Epub ahead of print]
40. 5-HT_{1A} and 5-HT_{2A} receptors affinity, docking studies and pharmacological evaluation of a series of 8-acetyl-7-hydroxy-4-methylcoumarin derivatives. Ostrowska K, Grzeszczuk D, Głuch-Lutwin M, Gryboś A, Siwek A, Leśniak A, Sacharczuk M, Trzaskowski B. *Bioorg Med Chem.* 2018 Jan 15;26(2):527-535. doi: 10.1016/j.bmc.2017.12.016. Epub 2017 Dec 9.
41. Modulation of the endocannabinoid system by the fatty acid amide hydrolase, monoacylglycerol and diacylglycerol lipase inhibitors as an attractive target for secretory diarrhoea therapy. Wasilewski A, Misicka A, Sacharczuk M, Fichna J. *J Physiol Pharmacol.* 2017 Aug;68(4):591-596.
42. Prosecretory effect of loperamide in ileal and colonic mucosae of mice displaying high or low swim stress-induced analgesia associated with high and low endogenous opioid system activity. Wasilewski A, Misicka A, Sacharczuk M, Fichna J. *Neurogastroenterol Motil.* 2018 Feb;30(2). doi: 10.1111/nmo.13166. Epub 2017 Jul 26.
43. B. Michalak, A. Filipek, P. Chomicki P, M. Pyza, M. Woźniak, B. Żyżyńska-Granica, J.P. Piwowski, A. Kicel, M.A. Olszewska, A.K. Kiss. Lignans From Forsythia x Intermedia Leaves and Flowers Attenuate the Pro-inflammatory Function of Leukocytes and Their Interaction With Endothelial Cells, *Frontiers in Pharmacology*, 2018, vol. 9, 401; doi: 10.3389/fphar.2018.00401; IF₂₀₁₇ = 3,831, MNiSzW₂₀₁₆ = 40.

44. M. Ordak, T. Nasierowski, E. Muszyńska. The growing problem of mephedrone use in Warsaw, Poland, 2010–18. *Lancet Psychiatry*, 2018, vol. 5(10), 787; doi: 10.1016/S2215-0366(18)30305-5 , IF₂₀₁₇ = 15,233; MNiSzW₂₀₁₆= 40.
45. M. Ordak, T. Nasierowski, M. Bujalska-Zadrozny. The problem of mephedrone in Europe: Causes and suggested solutions. *European Psychiatry*, 2018, vol. 55, 43-44, doi: 10.1016/j.eurpsy.2018.09.001, IF₂₀₁₇ =4,129, MNiSzW₂₀₁₆ = 35.
46. P. Poznanski A. Lesniak M. Korostynski M. Sacharczuk. Ethanol consumption following mild traumatic brain injury is related to blood-brain barrier permeability. *Addiction Biology*, 2018, doi: 10.1111/adb.12683, IF₂₀₁₇ = 5, 578, MNiSzW₂₀₁₆ = 40.
47. P. Poznański, A. Lesniak, M. Bujalska-Zadrozny, J. Strzemecka, M. Sacharczuk. Bidirectional selection for high and low stress-induced analgesia affects G-protein activity. *Neuropharmacology*, 2018, vol. 144, 37-42, doi: 10.1016/j.neuropharm.2018.10.014; IF₂₀₁₇ = 4,249, MNiSzW₂₀₁₆ = 40.
48. M.E. Czerwińska, E. Gąsińska, A. Leśniak, P. Krawczyk, A.K. Kiss, M. Naruszewicz, M. Bujalska-Zadrozny. Inhibitory effect of *Ligustrum vulgare* leaf extract on the development of neuropathic pain in a streptozotocin-induced rat model of diabetes. *Phytomedicine*, 2018, vol. 49, 75-82, doi: 10.1016/j.phymed.2018.06.006; IF₂₀₁₇ = 3,610, MNiSzW₂₀₁₆ = 40.
49. A. Lesniak , M. Aarnio, S. Diwakarla , T. Norberg, F. Nyberg, T. Gordh. Characterization of the binding site for d-deprenyl in human inflamed synovial membrane. *Life Sciences*, 2018, vol. 194, 26-33, doi: 10.1016/j.lfs.2017.12.003; IF₂₀₁₇ = 3,234 , MNiSzW₂₀₁₆ = 25.
50. A. de Cordé, P. Krząścik , R. Wolińska, P. Kleczkowska, M. Filip, M. Bujalska-Zadrozny. Disulfiram attenuates morphine or methadone withdrawal syndrome in mice. *Behavioural Pharmacology*, 2018, vol. 29 (5), 393-399, doi: 10.1097/FBP.0000000000000376; IF₂₀₁₇ = 1,854, MNiSzW₂₀₁₆ = 25.
51. A. Kowalczyk, P. Kleczkowska, M. Konop, K. Kasarełło, J. Czuwara, M. Pękala, P. Sosnowski, M. Sacharczuk, A. Cudnoch-Jędrzejewska, L. Rudnicka, M. Bujalska-Zadrozny. Determination of the anti-inflammatory properties and analgesic activity of the AA3052 chimeric peptide against CFA-induced inflammatory pain. *Animal Science Papers and Reports*, 2018, vol. 36, 219-240; IF₂₀₁₇= 0,71; MNiSzW₂₀₁₆ = 25 (czasopismo nie posiada nr doi).

52. A. Staniszevska, A. Lubiejewska, A. Czerw, M. Dąbrowska-Bender, A. Duda-Zalewska, D. Olejniczak, G. Juszczyk, M. Bujalska-Zadrożny. Awareness and attitudes towards clinical trials among Polish oncological patients who had never participated in a clinical trial. *Advances in Clinical and Experimental Medicine*, 2018, vol. 27 (4), 535-529; doi: 10.17219/acem/68762; IF₂₀₁₇= 1,262, MNiSzW₂₀₁₆ = 15.
53. P. P. Taciak, N. Lysenko, A.P. Mazurek. Drugs which influence serotonin transporter and serotonergic receptors: Pharmacological and clinical properties in the treatment of depression. *Pharmacological Reports*, 2018, vol. 70, 37-46; doi: 10.1016/j.pharep.2017.07.011; IF₂₀₁₇= 2,787 , MNiSzW₂₀₁₆ = 25.
54. K.P. Kubica, P.P. Taciak, A. Czajkowska, A. Stokfisz-Ignasiak, R. Wyrebiak, P. Podsadni, I. Młynarczuk-Biały, J. Malejczyk, A.P. Mazurek. Synthesis and ANTICANCER ACTIVITY EVALUATION OF SOME NEW DERIVATIVES OF 2-(4-BENZOYL-1-PIPERAZINYL)-QUINOLINE AND 2-(4-CINNAMOYL-1-PIPERAZINYL)-QUINOLINE. *Acta Poloniae Pharmaceutica - Drug Research* 2018, vol. 75, 891-901, doi: 10.32383/appdr/80098; IF₂₀₁₇= 0,531 , MNiSzW₂₀₁₆ = 15.
55. K.P. Kubica, P.P. Taciak, A. Czajkowska, A. Stokfisz-Ignasiak, R. Wyrebiak, P. Podsadni, I. Młynarczuk-Biały, J. Malejczyk, A.P. Mazurek. SYNTHESIS AND ANTICANCER ACTIVITY EVALUATION OF NOVEL DERIVATIVES OF 7-AMINO-4-METHYLQUINOLIN-2(1H)-ONE. *Acta Poloniae Pharmaceutica - Drug Research*, 2018, vol. 75, 903-910, doi: 10.32383/appdr/79279; IF₂₀₁₇= 0,531 , MNiSzW₂₀₁₆ = 15.
56. K. Ostrowska, D. Grzeszczuk, M. Głuch-Lutwin, A. Gryboś, A.Siwiek, A. Leśniak, M. Sacharczuk, B. Trzaskowski. 5-HT_{1A} and 5-HT_{2A} receptors affinity, docking studies and pharmacological evaluation of a series of 8-acetyl-7-hydroxy-4-methylcoumarin derivatives. *Bioorganic & Medicinal Chemistry*, 2018, vol. 26, 527-535, doi: 10.1016/j.bmc.2017.12.016; IF₂₀₁₇= 2,881, MNiSzW₂₀₁₆ = 25.
57. P. Kleczkowska, K. Nowicka, M. Bujalska- Zadrożny, E. Hermans. Neurokinin-1 receptor-based bivalent drugs in pain management: The journey to nowhere? *Pharmacology&therapeutics*. 2018; doi: 10.1016/j.pharmthera.2018.11.00; IF₂₀₁₇= 10,376 , MNiSzW₂₀₁₆ = 45.
58. P. Poznański, A. Leśniak, J. Strzemecka, M. Sacharczuk. Review of research on alcohol dependence in a model of mice selected for high and low stress-induced analgesia. *Health Problems of Civilization*. 2018;12(3):217-222. IF = 0, MNiSW = 9.

59. I. Kaszak, A. Ruszczak, Sz. Kanafa, K. Kacprzak, O. Witkowska Piłaszewicz, M. Sacharczuk, P. Jurka. New insights of canine mastitis. *Animal Science Papers and Reports* 2018;36(1):33-44. IF = 0.623, MNiSW = 25.
60. P. Poznański, A. Leśniak, A. Ruszczak, M. Sacharczuk. An unpredictable effect of opioid receptor antagonism in the treatment of alcohol use disorder. *Annual Report* 2018:25-28.
61. H. Zatorski, M. Salaga, M. Zielinska, A. Wasilewski, A. Misicka, M. Sacharczuk, J. Fichna. High activity of endogenous opioid system protects against gastric damage development in mouse models of gastric mucosal injury. *Pharmacological Reports* 2018: <https://doi.org/10.1016/j.pharep.2018.10.011>. IF = 2.787, MNiSW = 25.
62. M. Zielinska, A. Szymaszkiewicz, M. Salaga, H. Zatorski, J. Włodarczyk, D. Jacenik, R. Kordek, W.M. Krajewska, A. Misicka, J. Fichna, M. Sacharczuk. High activity of the endogenous opioid system and acute, but not chronic stress influence experimental colitis development in mice. *Journal of Physiology and Pharmacology* 2018, 69(5):1-9.